Flamel Technologies SA (FLML) was a big mover last session with shares rising nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent trend of the company, as the stock has now gained nearly 31% in the past one-month time frame.
This specialty pharmaceutical company has seen no estimate revision in the last 7 days. However, the Zacks Consensus Estimate has moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can last.
Flamel currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Better-ranked Med-Drug stocks worth considering include Lannett Company, Inc. (LCI), Shire plc (SHPG) and Questcor Pharmaceuticals, Inc. (QCOR). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
FLAMEL TECHNOLOGIES ADS (FLML): Free Stock Analysis Report
LANNETT COMP (LCI): Free Stock Analysis Report
SHIRE PLC ADS (SHPG): Free Stock Analysis Report
(QCOR): Free Stock Analysis Report
Zacks Investment Research